<DOC>
	<DOCNO>NCT01084135</DOCNO>
	<brief_summary>The purpose study determine short term use rivastigmine improve functional ability ( example , language , memory , executive function ) adolescents Down syndrome .</brief_summary>
	<brief_title>Rivastigmine Study Adolescents With Down Syndrome</brief_title>
	<detailed_description>This 24 week , double-blind , placebo control trial complete Clinical Research Unit Duke University Medical Center Kennedy Krieger Institute ( KKI ) . Sixteen evaluable subject enrol Duke 24 evaluable subject enrol KKI . The study consist four visit , screen visit ( -4 week ) , baseline visit ( week 0 ) ; safety visit week 10 , final/termination visit week 20 . The specific aim study : ) investigate efficacy rivastigmine tartrate treatment ; b ) build upon open-label treatment result overall function language improvement adolescent Down syndrome ( DS ) double-blind , placebo-controlled clinical trial ; c ) investigate specific cognitive domain may selectively respond rivastigmine tartrate treatment . The original IRB-approved protocol include Parent/Caregiver Rating Form Vineland Adaptive Behavior Scales- Second Edition ( VABS-II ) . The protocol amend replace Parent/Caregiver Rating Form Vineland Adaptive Behavior Scales- Second Edition ( VABS-II ) Vineland Adaptive Behavior Scales , Second Edition , Survey Interview Form . The protocol also amend extend trial 12 week 20 week . Due change amend protocol subject enrol prior IRB amendment include data analysis section .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Down Syndrome</mesh_term>
	<mesh_term>Rivastigmine</mesh_term>
	<criteria>1 . Correct VERBAL responses 7/9 Expressive One Word Picture Vocabulary Test item . 2 . Subject able put least 23 word together conversational speech . 3 . Subject 's speech understandable examiner majority time . 4 . Subjects good health medically stable 1 . Subject use sign language primary mean communication 2 . Subject medical history contraindicate use rivastigmine ( For example , patient active seizure disorder , asthma , celiac disease , heart disease heart rhythm disorder ) .</criteria>
	<gender>All</gender>
	<minimum_age>10 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>February 2015</verification_date>
	<keyword>Clinical trial</keyword>
	<keyword>Down syndrome</keyword>
	<keyword>adolescent</keyword>
	<keyword>cognitive</keyword>
	<keyword>rivastigmine</keyword>
</DOC>